Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Iaso Ventures is a Boston-based venture capital firm founded with a mission to catalyze innovation in the biodigital space, particularly in healthcare. Established to support the development of next-generation life sciences, the firm emphasizes collaboration with research hospitals, disease foundations, and pharma/medtech companies. This approach aims to accelerate growth and value creation in the healthcare sector.
The firm currently manages a team of 12 professionals, each bringing expertise in various fields such as data science, drug development, and clinical research. Iaso Ventures operates primarily in the United States, focusing on early-stage investments in companies that are pioneering advancements in brain health, behavioral health, and digital health.
Notable milestones include the launch of the NeuroImpact Fund in March 2024, in partnership with the Epilepsy Foundation, which targets epilepsy therapeutics and related innovations. Iaso Ventures continues to position itself as a leader in the healthcare investment landscape.
Iaso Ventures specializes in early-stage investments, primarily targeting Seed and Series A rounds. The firm focuses on startups that develop data-driven enabling technologies and platforms aimed at next-generation therapeutic development. Key sectors of interest include healthcare, AI, biotech, and digital health, with a particular emphasis on brain health, behavioral health, mental health, neurodegenerative diseases, and cognitive enhancement.
The firm seeks to invest in companies that are creating non-pharmacological interventions, AI-enabled drug discovery, drug design and delivery platforms, and digital health tools. Iaso Ventures leverages its deep sector expertise to foster innovation and accelerate growth, often collaborating with established research hospitals and industry experts to enhance the development of its portfolio companies.
Iaso Ventures has built a notable portfolio of companies that reflect its focus on healthcare innovation. Key investments include:
These companies exemplify Iaso Ventures' strategy of investing in innovative solutions that address critical healthcare challenges, particularly in the biodigital space.
Wasim Malik, PhD - Managing Partner; he has over a decade of experience as research faculty at Massachusetts General Hospital, focusing on clinical trials and psychiatric research.
John Reynders, PhD, MBA - Chief Data Scientist & Venture Partner; he brings expertise in data science and analytics to the firm.
Mark Currie, PhD - Venture Partner; he has a strong background in life sciences and drug development.
Michael Fenn, PhD - Venture Partner; he specializes in clinical research and therapeutic development.
Noah Richmond, JD, PhD - Executive in Residence; he provides legal and regulatory guidance.
Sharon Tan - Executive in Residence; she supports operational strategy and execution.
Anil Jina, MD - Executive in Residence; he focuses on clinical applications and healthcare delivery.
Sadiqa Mahmood - Entrepreneur in Residence; she mentors portfolio companies on business strategy.
Ray Sanchez, MD - Advisor, Drug Development; he has extensive experience in pharmaceutical development.
Maurizio Fava, MD - Advisor, Clinical R&D; he is a leader in clinical research methodologies.
Steve Schachter, MD - Advisor, Medtech; he provides insights into medical technology innovations.
Chandra Ramanathan, PhD, MBA - Advisor, Biotech; he specializes in biotechnology investments.
Craig DeLarge, MBA - Advisor, Digital Health; he focuses on digital health solutions and market trends.
To pitch Iaso Ventures, founders should use the contact email connect@iasoventures.com or submit their pitch through the website at iasoventures.com. A well-structured pitch deck should include an overview of the technology, market analysis, team qualifications, and financial projections. Founders should expect a response within a few weeks, and warm introductions are preferred but not mandatory.
In March 2024, Iaso Ventures co-launched the Iaso NeuroImpact Fund in partnership with the Epilepsy Foundation. This fund aims to focus on epilepsy therapeutics, seizure forecasting, and pediatric seizure prevention.
Throughout 2023-2024, Iaso Ventures has been actively deploying capital across biodigital and neurotech startups, reflecting its commitment to advancing healthcare innovation.
What are Iaso Ventures' investment criteria?
Iaso Ventures focuses on early-stage companies in the healthcare sector, particularly those developing data-driven technologies in brain health, behavioral health, and digital health. They look for startups that are creating non-pharmacological interventions and AI-enabled solutions.
How can I pitch to Iaso Ventures?
Founders can pitch Iaso Ventures through their website at iasoventures.com. It is advisable to include a clear overview of the technology, market potential, and team expertise in the pitch deck.
What makes Iaso Ventures different from other VC firms?
Iaso Ventures emphasizes a collaborative approach, partnering with research hospitals and industry experts to enhance the growth of its portfolio companies. Their focus on the biodigital space and brain health sets them apart in the venture capital landscape.
What is the geographic focus of Iaso Ventures?
The firm primarily operates in the United States, targeting startups that are innovating within the North American healthcare market.
What is the typical check size for investments?
While specific check sizes are not disclosed, Iaso Ventures typically invests in Seed and Series A rounds, which generally range from hundreds of thousands to several million dollars.
What kind of support do portfolio companies receive?
Iaso Ventures provides operational support, mentorship, and access to a network of industry experts and research institutions, enhancing the growth potential of their portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.